阿立哌唑与利培酮治疗精神分裂症的对照研究  

A controlled study of aripiprazole and risperidone in treatment of schizophrenia

作　　者：范文澜[1] 余成民[1] 李正发[1] 

机构地区：[1]南充精神卫生中心,四川南充637000

出　　处：《西部医学》2010年第6期1051-1052,共2页Medical Journal of West China

摘　　要：目的比较阿立哌唑与利培酮对精神分裂症的疗效及安全性。方法将60例精神分裂症患者随机分为两组,阿立哌唑组30例,利培酮组30例,疗程8周。在治疗前及治疗2、4、6、8周末分别采用阳性与阴性症状量表(PANSS)评定疗效,以治疗中出现的症状量表(TESS)评定药物不良反应。结果两组治疗后PANSS评分均有显著下降,阿立哌唑组与利培酮组的显效率分别为76.7%和73.3%,疗效相当。阿立哌唑组锥体外系副作用、体重增加和月经周期改变较利培酮组少而轻,且对催乳素水平没有影响。结论阿立哌唑与利培酮对精神分裂症均有较好的疗效,但阿立哌唑的药物不良反应比利培酮少,且不影响催乳素水平,是一种有效、安全的抗精神病药物。Objective To compare the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia.Methods 60 patients with schizophrenia were randomly divided into two groups： aripiprazole group（n=30） and risperidone group（n=30）.The therapeutic effects were evaluated by PANSS,and side effects were assessed by TESS before and after 2,4,6 and 8 treatment weeks.Results The rates of marked improvement in aripiprazole group and risperidone group were 76.7% and 73.3%,respectively.Conclusion Both aripiprazole and risperidone have good effective in the treatment of schizophrenia.But aripiprazole has less adverse effects.It＇s an effective and safe antipsychotic drug.

关 键 词：阿立哌唑 利培酮 精神分裂症 疗效 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学] R971.41[医药卫生—临床医学]